PDB Short entry for 2J9K HEADER HYDROLASE/HYDROLASE INHIBITOR 11-NOV-06 2J9K TITLE ATOMIC-RESOLUTION CRYSTAL STRUCTURE OF CHEMICALLY-SYNTHESIZED HIV-1 TITLE 2 PROTEASE COMPLEXED WITH INHIBITOR MVT-101 COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEASE; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: HIV1-PROTEASE; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 4 ORGANISM_TAXID: 11676; SOURCE 5 OTHER_DETAILS: CHEMICALLY SYNTHESIZED KEYWDS PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX, ASPARTYL PROTEASE, KEYWDS 2 HUMAN IMMUNODEFICIENCY VIRUS 1 EXPDTA X-RAY DIFFRACTION AUTHOR E.MALITO,Y.SHEN,E.C.B.JOHNSON,W.J.TANG REVDAT 7 13-DEC-23 2J9K 1 REMARK REVDAT 6 22-MAY-19 2J9K 1 REMARK LINK REVDAT 5 18-OCT-17 2J9K 1 REMARK REVDAT 4 13-JUL-11 2J9K 1 VERSN REVDAT 3 24-FEB-09 2J9K 1 VERSN REVDAT 2 16-OCT-07 2J9K 1 JRNL REVDAT 1 28-AUG-07 2J9K 0 JRNL AUTH E.C.B.JOHNSON,E.MALITO,Y.SHEN,B.PENTELUTE,D.RICH,J.FLORIAN, JRNL AUTH 2 W.J.TANG,S.B.H.KENT JRNL TITL INSIGHTS FROM ATOMIC-RESOLUTION X-RAY STRUCTURES OF JRNL TITL 2 CHEMICALLY SYNTHESIZED HIV-1 PROTEASE IN COMPLEX WITH JRNL TITL 3 INHIBITORS. JRNL REF J.MOL.BIOL. V. 373 573 2007 JRNL REFN ISSN 0022-2836 JRNL PMID 17869270 JRNL DOI 10.1016/J.JMB.2007.07.054 REMARK 2 REMARK 2 RESOLUTION. 1.20 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.20 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 93.8 REMARK 3 CROSS-VALIDATION METHOD : FREE R-VALUE REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.153 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.188 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.209 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.300 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 2832 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 53859 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.139 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.144 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.190 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.200 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 2330 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 44502 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1516 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 111 REMARK 3 SOLVENT ATOMS : 158 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 1819.0 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 1758.0 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 10 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 16656 REMARK 3 NUMBER OF RESTRAINTS : 21132 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.015 REMARK 3 ANGLE DISTANCES (A) : 0.034 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.031 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.084 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.085 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.051 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.004 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.042 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.087 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: ANISOTROPIC SCALING APPLIED BY THE REMARK 3 METHOD OF PARKIN, MOEZZI & HOPE, J.APPL.CRYST.28(1995)53-56 REMARK 4 REMARK 4 2J9K COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 11-NOV-06. REMARK 100 THE DEPOSITION ID IS D_1290030477. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL; NULL REMARK 200 TEMPERATURE (KELVIN) : 150; NULL REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y; Y REMARK 200 RADIATION SOURCE : APS; APS REMARK 200 BEAMLINE : 14-BM-C; 19-BM REMARK 200 X-RAY GENERATOR MODEL : NULL; NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M; M REMARK 200 WAVELENGTH OR RANGE (A) : 0.987; NULL REMARK 200 MONOCHROMATOR : NULL; NULL REMARK 200 OPTICS : NULL; NULL REMARK 200 REMARK 200 DETECTOR TYPE : NULL; NULL REMARK 200 DETECTOR MANUFACTURER : NULL; NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 56850 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.200 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.9 REMARK 200 DATA REDUNDANCY : 10.40 REMARK 200 R MERGE (I) : 0.10000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 33.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.20 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.24 REMARK 200 COMPLETENESS FOR SHELL (%) : 97.7 REMARK 200 DATA REDUNDANCY IN SHELL : 6.80 REMARK 200 R MERGE FOR SHELL (I) : 0.58000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 3.000 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH; SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: PDB ENTRY 7HVP REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 29.52 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.76 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.25M CITRATE, 0.5M PHOSPHATE, 30% REMARK 280 SATURATED AMMONIUM SULFATE, PH 6.0 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 25.28600 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 30.63550 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 29.38600 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 30.63550 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 25.28600 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 29.38600 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 TOTAL BURIED SURFACE AREA: 6100 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 11950 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -43.2 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 PHE A 99 C PHE A 99 OXT 0.154 REMARK 500 PHE B 99 C PHE B 99 OXT 0.135 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 8 NE - CZ - NH2 ANGL. DEV. = -4.3 DEGREES REMARK 500 ARG A 14 NE - CZ - NH2 ANGL. DEV. = -3.7 DEGREES REMARK 500 ARG B 14 CD - NE - CZ ANGL. DEV. = 15.8 DEGREES REMARK 500 GLU B 34 OE1 - CD - OE2 ANGL. DEV. = 7.7 DEGREES REMARK 500 LEU B 38 CA - CB - CG ANGL. DEV. = 15.2 DEGREES REMARK 500 ARG B 87 NE - CZ - NH1 ANGL. DEV. = 3.1 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU B 35 110.39 -33.90 REMARK 500 REMARK 500 REMARK: NULL REMARK 600 REMARK 600 HETEROGEN REMARK 600 REMARK 600 THE INHIBITOR HAS A REDUCED PEPTIDE BOND ISOSTERE REMARK 600 [CH2-NH] IN PLACE OF THE SCISSILE AMIDE REMARK 630 REMARK 630 MOLECULE TYPE: PEPTIDE-LIKE INHIBITOR REMARK 630 MOLECULE NAME: N-{(2S)-2-[(N-ACETYL-L-THREONYL-L-ISOLEUCYL)AMINO] REMARK 630 HEXYL}-L-NORLEUCYL-L-GLUTAMINYL-N~5~-[AMINO(IMINIO)METHYL]-L- REMARK 630 ORNITHINAMIDE REMARK 630 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 630 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 630 REMARK 630 M RES C SSSEQI REMARK 630 2NC A 0 REMARK 630 SOURCE: NULL REMARK 630 TAXONOMY: NULL REMARK 630 SUBCOMP: ACE THR ILE 2A0 GLN ARG NH2 REMARK 630 DETAILS: NULL REMARK 700 REMARK 700 SHEET REMARK 700 DETERMINATION METHOD: DSSP REMARK 700 THE SHEETS PRESENTED AS "AB" IN EACH CHAIN ON SHEET RECORDS REMARK 700 BELOW IS ACTUALLY AN 8-STRANDED BARREL THIS IS REPRESENTED BY REMARK 700 A 9-STRANDED SHEET IN WHICH THE FIRST AND LAST STRANDS REMARK 700 ARE IDENTICAL. REMARK 700 THE SHEETS PRESENTED AS "BA" IN EACH CHAIN ON SHEET RECORDS REMARK 700 BELOW IS ACTUALLY AN 7-STRANDED BARREL THIS IS REPRESENTED BY REMARK 700 A 8-STRANDED SHEET IN WHICH THE FIRST AND LAST STRANDS REMARK 700 ARE IDENTICAL. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 2NC A 0 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 1105 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 1106 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ACT A 1107 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ACT A 1108 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 1109 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 1110 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 1105 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC9 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 1106 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 1107 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ACT B 1108 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ACT B 1109 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ACT B 1110 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2J9J RELATED DB: PDB REMARK 900 UNSPECIFIED REMARK 999 REMARK 999 SEQUENCE REMARK 999 41S-LYSINE, 46 AND 56 NORLEUCINE, 67 AND 95 ALPHA- REMARK 999 AMINOBUTYRIC ACID DBREF 2J9K A 1 99 UNP O38907 O38907_9HIV1 1 99 DBREF 2J9K B 1 99 UNP O38907 O38907_9HIV1 1 99 SEQADV 2J9K LYS A 7 UNP O38907 GLN 7 CONFLICT SEQADV 2J9K NLE A 36 UNP O38907 MET 36 CONFLICT SEQADV 2J9K SLZ A 41 UNP O38907 ARG 41 CONFLICT SEQADV 2J9K NLE A 46 UNP O38907 MET 46 CONFLICT SEQADV 2J9K ILE A 62 UNP O38907 VAL 62 CONFLICT SEQADV 2J9K VAL A 64 UNP O38907 ILE 64 CONFLICT SEQADV 2J9K ILE A 93 UNP O38907 LEU 93 CONFLICT SEQADV 2J9K LYS B 7 UNP O38907 GLN 7 CONFLICT SEQADV 2J9K NLE B 36 UNP O38907 MET 36 CONFLICT SEQADV 2J9K SLZ B 41 UNP O38907 ARG 41 CONFLICT SEQADV 2J9K NLE B 46 UNP O38907 MET 46 CONFLICT SEQADV 2J9K ILE B 62 UNP O38907 VAL 62 CONFLICT SEQADV 2J9K VAL B 64 UNP O38907 ILE 64 CONFLICT SEQADV 2J9K ILE B 93 UNP O38907 LEU 93 CONFLICT SEQRES 1 A 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 A 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASP THR VAL ILE GLU GLU NLE ASN LEU PRO SEQRES 4 A 99 GLY SLZ TRP LYS PRO LYS NLE ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU SEQRES 6 A 99 ILE ABA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 A 99 GLN ILE GLY ABA THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 B 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASP THR VAL ILE GLU GLU NLE ASN LEU PRO SEQRES 4 B 99 GLY SLZ TRP LYS PRO LYS NLE ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU SEQRES 6 B 99 ILE ABA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 B 99 GLN ILE GLY ABA THR LEU ASN PHE MODRES 2J9K NLE A 36 LEU NORLEUCINE MODRES 2J9K SLZ A 41 LYS L-THIALYSINE MODRES 2J9K NLE A 46 LEU NORLEUCINE MODRES 2J9K ABA A 67 ALA ALPHA-AMINOBUTYRIC ACID MODRES 2J9K ABA A 95 ALA ALPHA-AMINOBUTYRIC ACID MODRES 2J9K NLE B 36 LEU NORLEUCINE MODRES 2J9K SLZ B 41 LYS L-THIALYSINE MODRES 2J9K NLE B 46 LEU NORLEUCINE MODRES 2J9K ABA B 67 ALA ALPHA-AMINOBUTYRIC ACID MODRES 2J9K ABA B 95 ALA ALPHA-AMINOBUTYRIC ACID HET NLE A 36 8 HET SLZ A 41 9 HET NLE A 46 8 HET ABA A 67 6 HET ABA A 95 6 HET NLE B 36 16 HET SLZ B 41 9 HET NLE B 46 8 HET ABA B 67 6 HET ABA B 95 6 HET 2NC A 0 54 HET SO4 A1105 5 HET SO4 A1106 5 HET ACT A1107 4 HET ACT A1108 4 HET GOL A1109 6 HET GOL A1110 6 HET SO4 B1105 5 HET SO4 B1106 5 HET SO4 B1107 5 HET ACT B1108 4 HET ACT B1109 4 HET ACT B1110 4 HETNAM NLE NORLEUCINE HETNAM SLZ L-THIALYSINE HETNAM ABA ALPHA-AMINOBUTYRIC ACID HETNAM 2NC N-{(2S)-2-[(N-ACETYL-L-THREONYL-L-ISOLEUCYL) HETNAM 2 2NC AMINO]HEXYL}-L-NORLEUCYL-L-GLUTAMINYL-N~5~- HETNAM 3 2NC [AMINO(IMINIO)METHYL]-L-ORNITHINAMIDE HETNAM SO4 SULFATE ION HETNAM ACT ACETATE ION HETNAM GOL GLYCEROL HETSYN 2NC P2/NC HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 1 NLE 4(C6 H13 N O2) FORMUL 1 SLZ 2(C5 H12 N2 O2 S) FORMUL 1 ABA 4(C4 H9 N O2) FORMUL 3 2NC C35 H68 N11 O8 1+ FORMUL 4 SO4 5(O4 S 2-) FORMUL 6 ACT 5(C2 H3 O2 1-) FORMUL 8 GOL 2(C3 H8 O3) FORMUL 16 HOH *158(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLY B 86 THR B 91 1 6 HELIX 3 3 GLN B 92 GLY B 94 5 3 SHEET 1 AA 2 GLN A 2 ILE A 3 0 SHEET 2 AA 2 LEU B 97 ASN B 98 -1 O LEU B 97 N ILE A 3 SHEET 1 AB 9 LEU A 10 ILE A 15 0 SHEET 2 AB 9 GLN A 18 LEU A 24 -1 O GLN A 18 N ILE A 15 SHEET 3 AB 9 ILE A 84 ILE A 85 1 N ILE A 85 O LEU A 23 SHEET 4 AB 9 VAL A 32 ILE A 33 -1 O VAL A 32 N ILE A 84 SHEET 5 AB 9 LYS A 70 VAL A 77 1 O LEU A 76 N ILE A 33 SHEET 6 AB 9 GLY A 52 GLU A 65 -1 O ARG A 57 N VAL A 77 SHEET 7 AB 9 LEU A 10 ILE A 15 -1 O ARG A 14 N GLU A 65 SHEET 8 AB 9 GLN A 18 LEU A 24 -1 O GLN A 18 N ILE A 15 SHEET 9 AB 9 LEU A 10 ILE A 15 -1 O VAL A 11 N ALA A 22 SHEET 1 AC 2 LEU A 97 ASN A 98 0 SHEET 2 AC 2 GLN B 2 ILE B 3 -1 O ILE B 3 N LEU A 97 SHEET 1 BA 8 LEU B 10 ILE B 15 0 SHEET 2 BA 8 GLN B 18 LEU B 24 -1 O GLN B 18 N ILE B 15 SHEET 3 BA 8 ILE B 84 ILE B 85 1 N ILE B 85 O LEU B 23 SHEET 4 BA 8 VAL B 32 ILE B 33 -1 O VAL B 32 N ILE B 84 SHEET 5 BA 8 LYS B 70 VAL B 77 1 O LEU B 76 N ILE B 33 SHEET 6 BA 8 GLY B 52 GLU B 65 -1 O ARG B 57 N VAL B 77 SHEET 7 BA 8 LEU B 10 ILE B 15 -1 O ARG B 14 N GLU B 65 SHEET 8 BA 8 LEU B 10 ILE B 15 0 LINK C GLU A 35 N NLE A 36 1555 1555 1.32 LINK C NLE A 36 N ASN A 37 1555 1555 1.32 LINK C GLY A 40 N SLZ A 41 1555 1555 1.34 LINK C SLZ A 41 N TRP A 42 1555 1555 1.33 LINK C LYS A 45 N NLE A 46 1555 1555 1.31 LINK C NLE A 46 N ILE A 47 1555 1555 1.32 LINK C ILE A 66 N ABA A 67 1555 1555 1.32 LINK C ABA A 67 N GLY A 68 1555 1555 1.34 LINK C GLY A 94 N ABA A 95 1555 1555 1.31 LINK C ABA A 95 N THR A 96 1555 1555 1.33 LINK C BGLU B 35 N BNLE B 36 1555 1555 1.32 LINK C AGLU B 35 N ANLE B 36 1555 1555 1.36 LINK C BNLE B 36 N BASN B 37 1555 1555 1.34 LINK C ANLE B 36 N AASN B 37 1555 1555 1.33 LINK C GLY B 40 N SLZ B 41 1555 1555 1.32 LINK C SLZ B 41 N TRP B 42 1555 1555 1.33 LINK C LYS B 45 N NLE B 46 1555 1555 1.33 LINK C NLE B 46 N ILE B 47 1555 1555 1.33 LINK C ILE B 66 N ABA B 67 1555 1555 1.32 LINK C ABA B 67 N GLY B 68 1555 1555 1.35 LINK C GLY B 94 N ABA B 95 1555 1555 1.31 LINK C ABA B 95 N THR B 96 1555 1555 1.33 SITE 1 AC1 26 ARG A 8 ASP A 25 GLY A 27 ALA A 28 SITE 2 AC1 26 ASP A 29 ASP A 30 ILE A 47 GLY A 48 SITE 3 AC1 26 GLY A 49 ILE A 50 VAL A 82 HOH A2011 SITE 4 AC1 26 HOH A2028 HOH A2031 HOH A2079 HOH A2080 SITE 5 AC1 26 HOH A2081 ARG B 8 ASP B 25 GLY B 27 SITE 6 AC1 26 ALA B 28 ASP B 29 ASP B 30 GLY B 48 SITE 7 AC1 26 GLY B 49 VAL B 82 SITE 1 AC2 5 PRO A 1 ARG A 57 HIS A 69 HOH A2058 SITE 2 AC2 5 HOH B2073 SITE 1 AC3 5 GLY A 73 THR A 74 ASN A 88 HOH A2029 SITE 2 AC3 5 HOH A2070 SITE 1 AC4 3 LYS A 7 ARG A 8 HOH A2010 SITE 1 AC5 6 LYS A 55 ARG A 57 GLY A 68 HOH A2038 SITE 2 AC5 6 HOH A2052 HOH A2056 SITE 1 AC6 8 PHE A 99 HOH A2060 HOH A2078 NLE B 46 SITE 2 AC6 8 PHE B 53 LYS B 55 HIS B 69 SO4 B1107 SITE 1 AC7 4 VAL A 11 THR A 12 SLZ A 41 TRP A 42 SITE 1 AC8 8 ARG A 14 HOH A2016 ARG B 14 GLY B 17 SITE 2 AC8 8 PRO B 63 HOH B2055 HOH B2075 HOH B2076 SITE 1 AC9 6 HIS A 69 LYS A 70 HOH A2060 PRO B 1 SITE 2 AC9 6 LYS B 55 SO4 B1107 SITE 1 BC1 7 HIS A 69 GOL A1109 HOH A2059 PRO B 1 SITE 2 BC1 7 HIS B 69 SO4 B1106 HOH B2074 SITE 1 BC2 6 GLY B 73 THR B 74 ASN B 88 GLN B 92 SITE 2 BC2 6 HOH B2062 HOH B2066 SITE 1 BC3 1 ARG B 8 SITE 1 BC4 3 LYS A 55 LYS A 70 LYS B 70 CRYST1 50.572 58.772 61.271 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019774 0.000000 0.000000 0.00000 SCALE2 0.000000 0.017015 0.000000 0.00000 SCALE3 0.000000 0.000000 0.016321 0.00000